Literature DB >> 32675153

Lessons of the month 2: Chronic eosinophilic pneumonia (CEP): A rare manifestation of infliximab therapy.

Iftikhar Nadeem1, Usman Khatana2, Masood Ur Rasool3, Asma Wasil2, Mohammed Azher2.   

Abstract

We present a rare and unusual case of 22-year-old man who was on infliximab therapy for his uncontrolled ulcerative colitis. Infliximab was stopped as he didn't get any benefit from it and he ended up having subtotal colectomy and ileostomy. He presented with shortness of breath and eosinophilia and underwent a number of investigations and finally a diagnosis of chronic eosinophilia secondary to infliximab was made. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  Chronic eosinophilic pneumonia; infliximab antibodies; infliximab therapy; pharmacology

Mesh:

Substances:

Year:  2020        PMID: 32675153      PMCID: PMC7385780          DOI: 10.7861/clinmed.2020-0271

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  5 in total

1.  Invasive pulmonary aspergillosis associated with infliximab therapy.

Authors:  A Warris; A Bjørneklett; P Gaustad
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Pulmonary Eosinophilia Following Infliximab Treatment for Crohn's Disease.

Authors:  David T Rubin; Sunana Sohi; Rebecca A Shilling; Steven R White
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

3.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 4.  Hypersensitivity reactions to biological drugs.

Authors:  M Corominas; G Gastaminza; T Lobera
Journal:  J Investig Allergol Clin Immunol       Date:  2014       Impact factor: 4.333

5.  Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease.

Authors:  Sofia Panagi; Wojciech Palka; Burton I Korelitz; Metin Taskin; Klaus D Lessnau
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.